Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 10/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927479 | 1.00 | CXCR3 (0.46) | CXCR3NAMPTFNTAFNTBTP53 | |
| SCHEMBL19927484 | 1.00 | CXCR3 (0.46) | CXCR3NAMPTFNTAFNTBTP53 | |
| SCHEMBL19931782 | 0.92 | CXCR3 (0.51) | CXCR3NAMPTFNTAFNTBHDAC8 | |
| SCHEMBL21543975 | 0.92 | CXCR3 (0.51) | CXCR3NAMPTFNTAFNTBHDAC8 | |
| SCHEMBL21543974 | 0.92 | CXCR3 (0.51) | CXCR3NAMPTFNTAFNTBHDAC8 | |
| SCHEMBL19931586 | 0.88 | CXCR3 (0.47) | CXCR3NAMPTFNTAFNTBHDAC8 | |
| SCHEMBL19927191 | 0.88 | MMP8 (0.48) | CXCR3TP53HDAC8 | |
| SCHEMBL19927194 | 0.88 | MMP8 (0.48) | CXCR3TP53HDAC8 | |
| SCHEMBL19927192 | 0.88 | MMP8 (0.48) | CXCR3TP53HDAC8 | |
| SCHEMBL30377839 | 0.88 | CXCR3 (0.39) | CXCR3HDAC8PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3507275-A1 | CXCR3 RECEPTOR AGONISTS | Celgene International II Sarl (CH) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | CXCR3 1/4885NAMPT 2081/4885FNTA 3918/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | CXCR3 1/4885NAMPT 2081/4885FNTA 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.